Breast Cancer News
Follow
Find
53.1K views | +28 today
 
Scooped by Susan Zager
onto Breast Cancer News
Scoop.it!

Ask Your US Representative to Support HR 1801 Today!

Ask Your US Representative to Support HR 1801 Today! | Breast Cancer News | Scoop.it

"The Cancer Drug Coverage Parity Act has been reintroduced and now has over 80 bi-partisan co-sponsors! But the work is not done yet. The more bi-partisan co-sponsors we have, the more likely the House will move to vote on this critical legislation.

We need you to reach out to your US Representative to ask him or her to co-sponsor HR 1801. The bill will require oral anticancer treatments to be covered at the same rate as IV treatments. Many insurance plans treat patient-administered anticancer treatments, like oral pills, differently than other forms of treatment creating a financial barrier to care for many myeloma patients.

By entering your information below, you will be able to quickly and easily email your US Representative a prewritten letter.  After clicking next, take a moment to customize the letter with a personal story to increase your message's impact. You can share your story or click on the talking points to the right to add those into your message.

Thank you for your help ensuring cancer patients have fair and equal access to all types of treatments!"


Susan Zager's insight:

Please use the International Myeloma Association's prewritten letter to Congress and write to your representatives to support this important bipartisan legislation  (HR 1801)/  It will assure that all cancer patients can receive oral as well as IV anti-cancer treatments treated the same way so that the oral medications are not a financial burden. 

more...
Tambre Leighn's curator insight, July 31, 2014 11:51 AM

Your voice counts...take action, create change.  Equal reimbursement for oral chemotherapy...it's the right thing to do.

Latest News, Research, and Articles of Interest
Curated by Susan Zager
Your new post is loading...
Your new post is loading...
Scooped by Susan Zager
Scoop.it!

New breast exam nearly quadruples detection of invasive breast cancers in women with dense breast tissue

New breast exam nearly quadruples detection of invasive breast cancers in women with dense breast tissue | Breast Cancer News | Scoop.it

For more information go to the study at: Molecular Breast Imaging (MBI) is a supplemental imaging technology designed to find tumors that would otherwise be obscured by surrounding dense breast tissue on a mammogram. The new breast imaging technique nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study.

Susan Zager's insight:

For more information go to: http://www.ajronline.org/doi/abs/10.2214/AJR.14.13357


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

A Fascinating Year in Breast Cancer Advances

A Fascinating Year in Breast Cancer Advances | Breast Cancer News | Scoop.it

Some of the most important advances in breast cancer this year were related to all kinds of heterogeneity: within tumors, between tumors in a single patient, and between tumors in early and later stages, according to oncologists speaking at conferences, and contacted by Bioscience Technology.

“This year we had a lot of fascinating stories,” Jorge Reis-Filho told the San Antonio Breast Cancer Symposium in December. Reis-Filho is a cancer geneticist at Memorial Sloan Kettering Cancer Center. Among the most important stories, he said, was the repeated confirmation, due to improving technology and massive genetics projects, that “heterogeneity is incredibly prevalent.”

Other areas of note, said oncologists, included findings that PALB2 is a strong germ-line proclivity gene; that drugs can be added to Herceptin to increase its potency; that ovarian suppression can work on some populations; and that long-term tamoxifen can prompt estrogen-induced apoptosis. 

PALB2

Daniel Hayes, a University of Michigan Cancer Center oncologist, told Bioscience Technology that one of the great papers of 2014 involved “identification of germ-line inherited mutations other than BRCA1 and 2 that increase susceptibility/risk for breast cancer.” The New England Journal of Medicine (NEJM) paper, by Addenbrooke’s Hospital’s Marc Tischkowitz, found that patients with a mutation in the PALB2 gene stand a one in three chance of getting breast cancer by age 70. The gene interacts with the deadly BRCA1 and BRCA2, and has been called the potential “BRCA3.”

Susan Zager's insight:

For more information go to:

(1) http://www.nejm.org/doi/full/10.1056/NEJMoa1404037

(2) http://www.ncbi.nlm.nih.gov/pubmed/24525703

(3) http://www.nature.com/nature/journal/v512/n7513/full/nature13600.html

(4) http://annonc.oxfordjournals.org/content/25/8/1544.full?sid=391b8ae3-97b6-46f6-903b-5c3475ddaa6a

(5) http://cancerres.aacrjournals.org/content/early/2014/10/10/0008-5472.CAN-14-1784





more...
Jose Rodrigues's curator insight, January 6, 9:45 PM
The World need and wait for this. Great and important ecencial advances in research and apllication of Know How.
Scooped by Susan Zager
Scoop.it!

SABCS 2014: Immunotherapy Shows Early Promise for Triple-negative Breast Cancer Patients - CANCER RESEARCH Catalyst

SABCS 2014: Immunotherapy Shows Early Promise for Triple-negative Breast Cancer Patients - CANCER RESEARCH Catalyst | Breast Cancer News | Scoop.it

"After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope for women with a very challenging form of breast cancer—triple-negative breast cancer.

Data presented Dec. 10 at the San Antonio Breast Cancer Symposium showed that the PD-1 inhibitor pembrolizumab (Keytruda) was well tolerated by women with recurrent or metastatic triple-negative breast cancer and showed early signs of effectiveness. The PD-L1 inhibitor MPDL3280A was also found to be safe and tolerable for women with metastatic triple-negative breast cancer, with tumor shrinkage in some women.

Pembrolizumab Trial

This phase I, nonrandomized multicenter trial involved 32 patients from 29 to 72 years old who had heavily pretreated recurrent or metastatic triple-negative breast cancer. Patients received intravenous infusions of pembrolizumab every two weeks. Safety and tolerability of the drug—the standard endpoints of a phase I trial—were assessed, as well as antitumor activity."

Susan Zager's insight:

According to the article, "Triple-negative breast cancer is an area of active research,” says Nanda. “We are learning more about the different subtypes and are working hard to develop targeted approaches for patients with all forms of this disease. I would encourage patients with triple-negative breast cancer to consider enrolling in clinical trials if possible, so that together we can advance our understanding of these tumors and improve outcomes for women with this form of breast cancer.”

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

SABCS 2014: Researchers present progression-free survival results from BOLERO-1 trial. ecancer - News

SABCS 2014: Researchers present progression-free survival results from BOLERO-1 trial. ecancer - News | Breast Cancer News | Scoop.it

"Results from the final analysis of progression-free survival, response rate, and safety for the randomised, phase III Breast Cancer Trials of Oral Everolimus-1 (BOLERO-1) were presented at the 2014 San Antonio Breast Cancer Symposium.

“BOLERO-1 is a randomised, double-blind, phase III clinical trial evaluating whether the addition of everolimus, an mTOR inhibitor, to trastuzumab and paclitaxel improves progression- free survival for patients with HER2-positive, advanced breast cancer who have received no prior treatments for advanced disease,” said Sara A. Hurvitz, MD, an associate clinical professor of medicine and director of the Breast Oncology Program in the University of California, Los Angeles, Division of Haematology/Oncology.

“In San Antonio, we will be presenting data on progression-free survival for the overall patient population and in the subpopulation of patients with hormone receptor-negative disease,” continued Hurvitz. “We will also show our analysis of secondary endpoints of the study, including safety.”

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Triple Negative Breast Cancer impacts Mexican women

Triple Negative Breast Cancer impacts Mexican women | Breast Cancer News | Scoop.it
Though Hispanic women typically have lower rates of breast cancer diagnosis compared to non-Hispanic white women, when it comes to triple-negative breast cancer, the situations are reversed. Not on...
Susan Zager's insight:

For more information go to:: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=2632#.VHj0Xyc3vig


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform | Breast Cancer News | Scoop.it

"The trial will include breast cancer patients with low expression of HER2

Synthon Biopharmaceuticals (‘Synthon’) today announced that the first patients with metastatic solid tumors have commenced treatment with its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985.

First patients for this trial are being enrolled in leading European oncology centers Radboud University Medical Center (Nijmegen, the Netherlands), the Jules Bordet Institute (Brussels, Belgium) and the Institute of Cancer Research at The Royal Marsden Hospital (London, United Kingdom). The trial will recruit at least 76 patients and more centers are expected to join the trial in 2015.

This trial is a two part first-in-human Phase I study. In the dose escalation part of the trial, safety and efficacy of SYD985 will be evaluated in patients with locally advanced or metastatic solid tumors of any origin. In the expanded cohort part of the trial, only patients with breast and gastric cancer will be enrolled. The expanded cohorts will include patients currently indicated for HER2-targeted treatment as well as patients with HER2 2+ and HER2 1+ breast cancer for whom there currently is no effective anti-HER2 therapy available."

Susan Zager's insight:

This trial is registered in ClinicalTrials.gov with identifier NCT02277717. For more information go to: http://europepmc.org/abstract/med/25189543


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

IRCM Jean-François Côté Molecular and Cellular Biology Axl

IRCM Jean-François Côté Molecular and Cellular Biology Axl | Breast Cancer News | Scoop.it

"Montreal, QC - A team of researchers at the IRCM, led by Jean-François Côté, have discovered a potential new therapeutic target to prevent the invasion of cancer cells, which could have a significant impact on breast cancer treatment. Their breakthrough was published online this week by the scientific journal Molecular and Cellular Biology.

The researchers are interested in understanding the molecular details involved in metastasis, which is the spread of cancer from one organ to another. This harmful process accounts for nearly 90 percent of cancer patient deaths.

"We investigated a molecule called Axl, which is detected at the surface of cancer cells and is known to be involved in various types of invasive cancer," said Dr. Côté, director of the Cytoskeletal Organization and Cell Migration research unit at the IRCM. "In fact, a high amount of Axl on breast tumours is closely associated with metastasis and a poor prognosis for patients. The molecule's mechanisms remain poorly understood, but we are now excited to have found how it works inside the cell."

Susan Zager's insight:

To see the study go to: http://mcb.asm.org/content/early/2014/10/14/MCB.00764-14.abstract


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Findings point to an "off switch" for drug resistance in cancer

Findings point to an "off switch" for drug resistance in cancer | Breast Cancer News | Scoop.it

"LA JOLLA–Like a colony of bacteria or species of animals, cancer cells within a tumor must evolve to survive. A dose of chemotherapy may kill hundreds of thousands of cancer cells, for example, but a single cell with a unique mutation can survive and quickly generate a new batch of drug-resistant cells, making cancer hard to combat.

Now, scientists at the Salk Institute have uncovered details about how cancer is able to become drug resistant over time, a phenomenon that occurs because cancer cells within the same tumor aren’t identical–the cells have slight genetic variation, or diversity. The new work, published October 20 in PNAS, shows how variations in breast cancer cells’ RNA, the molecule that decodes genes and produces proteins, helps the cancer to evolve more quickly than previously thought. These new findings may potentially point to a “switch” to turn off this diversity–and thereby drug resistance–in cancer cells. "

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Metastatic Breast Cancer: A Look at the Critical Need for Focused Research

Metastatic Breast Cancer: A Look at the Critical Need for Focused Research | Breast Cancer News | Scoop.it
I'm the oldest of four siblings, so I didn't have an older brother or sister to "look up to" when I was growing up. But I did have a cousin (actually a second cousin) who I admired as a teen. Wanda...
Susan Zager's insight:

Take a look at: 13 Facts Everyone should know about Breast Cancer - http://mbcn.org/developing-awareness/category/13-things-everyone-should-know-about-metastatic-breast-cancer from the Metastatic Breast Cancer Network. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Autumn colors are proof of God’s existence

Autumn colors are proof of God’s existence | Breast Cancer News | Scoop.it

"Until earlier this week, I had 20/20 vision, but thanks to a rare side effect from a necessary medical procedure, that’s no longer true.

I had stepped into the hyperbaric oxygen chamber in hopes of healing my jaw necrosis. If you haven’t heard of the chamber, it is used for wounds that will not heal.

Instead, I got cataracts— a one-in-a-billion side effect.

After receiving 20 of the 40 sessions prescribed for me, I was driving home and thought it odd that I could barely see the street signs that came my way. Then I remembered one of the men in the chamber had said that he became near-sighted after his first round of sessions (it was now a year later, and he was trying it again). He said the near-sightedness lasted for about three weeks, and then his eyesight returned to normal.  

As usual— thinking like Mary Poppins, as I often do— I thought, “That could never happen to me!”  But everything happens to me."  

Susan Zager's insight:

"Noreen Fraser is living with Stage IV metastatic breast cancer. She is the Founder and CEO of the Noreen Fraser Foundation, a 501(c)(3) non-profit organization dedicated to funding groundbreaking women's cancer research."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Support Armed Forces Breast Cancer Research Act (H.R. 4869)

Support Armed Forces Breast Cancer Research Act (H.R. 4869) | Breast Cancer News | Scoop.it

"Dear Hon. John Boehner,

More than 200,000 Americans are diagnosed with invasive breast cancer each year, and recent research suggests that military service members are disproportionately affected. In fact, more women have been evacuated from the theaters in Iraq and Afghanistan for breast cancer-related causes than any other reason. While some of this startling increase may be attributed to more sophisticated methods of detection as well as more frequent examinations, this does not account for the staggering difference in our veterans.

Unfortunately, since the Department of Veterans Affairs currently fails to recognize breast cancer as a service-related disability, veterans remain ineligible for the health coverage they earned through their service. When Rep. Boswell introduced the Armed Forces Breast Cancer Research Act (H.R. 4869) to the House of Representatives in May, he took an important and necessary step towards correcting this disparity. The time has come for you and your congressional colleagues to continue the work of Boswell and make this bill into law.

Susan Zager's insight:

Please read and sign this petition. It is unacceptable that our military personnel are not covered for breast cancer treatments.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Immunotherapy vaccine shows promise in preventing recurrence

Immunotherapy vaccine shows promise in preventing recurrence | Breast Cancer News | Scoop.it

"A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence.

This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings are being presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology’s Breast Cancer Symposium in San Francisco.

Advertisement

“This is an important and different avenue in immunotherapy research, in that we are investigating ways to prevent cancer recurrence by stimulating the immune system to treat cancer,” says principal investigator Elizabeth Mittendorf, M.D., Ph.D., associate professor of Surgical Oncology. “The ultimate goal is to develop a preventative tool that will minimize the risk of recurrence in women who have already had breast cancer and for whom standard therapies have failed.”

One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57 percent. Further, women with the highest overexpression of HER2, also known as HER2 +3, had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. HER2 is an oncoprotein that promotes tumor growth and is expressed to some extent in 75-80 percent of breast cancers.


Susan Zager's insight:

To see the study go to: http://meetinglibrary.asco.org/content/136978-151


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

More high-risk surgical patients are choosing breast reconstruction procedures after mastectomy

More high-risk surgical patients are choosing breast reconstruction procedures after mastectomy | Breast Cancer News | Scoop.it
The number of breast cancer patients undergoing immediate breast reconstruction operations after mastectomy has grown steadily over the past 15 years, according to new research. the overall success rate in the high-risk population is over 88 percent, which the study authors consider high, although complications such as implant explantation and flap problems do occur.
Susan Zager's insight:

To see the study go to: http://www.journalacs.org/article/S1072-7515(14)00444-X/abstract


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Gene linked to aggressive breast cancer

Gene linked to aggressive breast cancer | Breast Cancer News | Scoop.it

"UK scientists have linked(link is external) an overactive gene to an aggressive type of breast cancer.

The team, from the Wellcome Trust Sanger Institute and the University of Cambridge, identified the BCL11A gene as especially active in ‘triple negative’ breast cancer – an aggressive form of the disease accounting for about one in five cases.

"This study is a promising step forward" - Dr Emma Smith, Cancer Research UK

Welcoming the findings – based on an analysis of cancer samples from almost 3000 women - Dr Emma Smith, senior science information officer at Cancer Research UK, said: “Figuring out the genes that play a role in triple negative breast cancer could lead to new ways to tackle the disease - so this study is a promising step forward.

“The next steps will be finding out if the gene plays the same role in causing breast cancer in women, and whether drugs can be developed to target the faulty molecules," she added.

Breast cancer is now known to exist in 10 distinct subtypes based on tumours’ genetic make-up. Most triple-negative breast cancer tumours are of a genetic type called ‘basal-like’.

BCL11A was found to be overactive in tumour samples from around eight in 10 patients with ‘basal-like’ disease.

Prognosis for triple negative cancers is poorer than for other forms, and limited knowledge of the distinct genetic properties of the disease has made the development of new treatments difficult.

Therapies used in treating other subtypes – such as trastuzumab and tamoxifen – do not work on this type of cancer, because tumour cells lack three different ‘receptor’ molecules that are targeted by the treatments."

Susan Zager's insight:

To read the study in Nature Communications go to: http://www.nature.com/ncomms/2015/150109/ncomms6987/full/ncomms6987.html


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

FDA grants fast track status to IMMU-132 for triple-negative breast cancer | Hematology Oncology

FDA grants fast track status to IMMU-132 for triple-negative breast cancer | Hematology Oncology | Breast Cancer News | Scoop.it
Hematology Oncology | The FDA today granted fast track status to sacituzumab govitecan, an antibody–drug conjugate in development for treatment of patients with triple-negative breast cancer who failed prior therapies for metastatic disease, according to the drug’s manufacturer.Sacituzumab govitecan (IMMU-132, Immunomedics) is formed by using the moderately-toxic SN-38 — the active metabolite of
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit

20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit | Breast Cancer News | Scoop.it

"Five years of tamoxifen provided 20 years of breast cancer prevention to some at-risk women who took it prophylactically.

However, their 20-year all-cause mortality was no different from those taking placebo (182 vs. 166 deaths), nor was their mortality from breast cancer (31 vs. 26, respectively), Jack Cuzick, Ph.D., said at the San Antonio Breast Cancer Symposium.

“While we saw clear, lasting benefits of tamoxifen in reducing breast cancer incidence, uncertainty with respect to mortality remains,” said Dr. Cuzick, the John Snow professor of epidemiology at Wolfson Institute of Preventive Medicine at Queen Mary University, London.

He suggested that, in light of the small number of deaths, the study was not sufficiently powered to detect any significant survival difference. But women in the IBIS-1 trial will continue to be observed, and future analyses could clarify the issue, he added.

“Although 20 years seems like a long follow-up time, it is actually too early to make any clear statement about mortality,” he said. “However, we are concerned about an excess emergence of ER-negative tumors, which we saw after 10 years.”

The study was simultaneously published on Dec. 13 in Lancet Oncology"

Susan Zager's insight:

To see the published study on Dec 13 in Lance Oncology, go to: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971171-4/fulltext


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New breast cancer vaccine proves safe in early clinical trial

New breast cancer vaccine proves safe in early clinical trial | Breast Cancer News | Scoop.it
Results of an early clinical trial suggest that a breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer.
Susan Zager's insight:

To see the study go to: http://clincancerres.aacrjournals.org/content/20/23/5964.abstract


more...
Erika Kettlewell's curator insight, December 4, 2014 3:11 AM

A study from Washington University School of Medicine has developed a vaccine to help fight breast cancer. So far they have tested the vaccine on 14 patients who have so far seen improvements such as slowing down the growth rate of the cancer cells and in half of the women actually stopped the progression of the cancer all together. This is a great step in finding a cure for breast cancer!! 

Scooped by Susan Zager
Scoop.it!

'3 specific cells' combo behind breast cancer spread, confirm scientists | Latest News & Updates at Daily News & Analysis

'3 specific cells' combo behind breast cancer spread, confirm scientists | Latest News & Updates at Daily News & Analysis | Breast Cancer News | Scoop.it
'3 specific cells' combo behind breast cancer spread, confirm scientists - In a new study, scientists have found that it is the specific trio of cells that causes breast cancer to spread.
A study, led by researchers at the NCI-designated Albert Einstein Cancer Center and Montefiore Einstein Center for Cancer Care, combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far, and the findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
Susan Zager's insight:

For more information go to: http://stke.sciencemag.org/content/7/353/ra112.abstract


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New Cancer Therapy: Using Oncolytic Viruses to Treat Metastatic Disease | Physicians News

"There exists a “type” of cancer that is common yet rarely discussed—metastatic disease, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Each year, at least 2.6 million people in the developed world die of cancers that have metastasized. Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or “mets.”

Could a virus be the key to finally beating the mets? The question is not as odd as it might sound. Virotherapy or oncolytic virus therapy involves the conversion of viruses into cancer-fighting agents by reprogramming them to attack cancerous cells, while healthy cells remain relatively undamaged. Specifically, viruses can be harnessed to infect, multiply within and subsequently lyse cancer cells; the virus targets the tumor and protects normal tissue.

Several types of oncolytic viruses have been developed to date. One of them, the reovirus, is a non-enveloped virus with a double-stranded, segmented RNA genome that forms particles that are 60 to 90 nm. The reovirus preferentially replicates in cancer cells that feature a common mutation known as an “activated Ras pathway,” while sparing normal cells. This makes it intrinsically tumor selective without the need for any genetic manipulation."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

CyberKnife Treatment Helps Metastatic Breast Cancer Patient

CyberKnife Treatment Helps Metastatic Breast Cancer Patient | Breast Cancer News | Scoop.it

"RENO, Nev., Oct. 21, 2014 /PRNewswire/ -- As the second-most diagnosed cancer in women in the U.S., breast cancer impacts the lives of many. Debbie Black, a Nevada resident, is among those whose life has been dramatically impacted by the disease.

Initially diagnosed with stage II breast cancer at the age of 30, Black underwent aggressive chemotherapy and hormonal treatment. She was cancer-free for more than a decade until she began experiencing the loss of feeling in the left side of her body.

Following tests, Black learned her cancer had come back and spread to her brain. She underwent surgery to remove the majority of the brain tumor, but due to the tumor's size and proximity to critical anatomy, a small portion had to be left behind. Additionally, it was discovered that a second smaller tumor had formed in her brain. Black's doctors suggested CyberKnife to treat both the original remaining tumor and the second tumor discovered.

"CyberKnife was the most amazing treatment I had ever experienced," said Black. "It was a piece of cake and walk in the park compared to past treatments I had undergone."

more...
Wy Woods Harris's curator insight, October 23, 2014 10:12 AM

I am looking at what might benefit the cancer care and cure community.

 

Scooped by Susan Zager
Scoop.it!

Anne Loeser: Reverse trends about breast cancer

Anne Loeser: Reverse trends about breast cancer | Breast Cancer News | Scoop.it

"Imagine that you have an acquaintance in Springfield, Massachusetts, a city best known as the birthplace of basketball and home of the Basketball Hall of Fame. The fourth largest city in New England, Springfield boasts 155,000 residents of various ethnicities and religious beliefs.

Now envision that over the next five years, 120,900 (78 percent) of Springfield’s citizens pass away, and only 3,100 (2 percent) survive a normal life span.

In the event of such a situation, you’d expect considerable media coverage and public outrage. But the deaths continue mostly unnoticed.

If you believe such a circumstance to be unthinkable, think again.

Including myself, an estimated 155,000 Americans — the population of Springfield, — are living with metastatic breast cancer (MBC). MBC is cancer that has traveled from the breast and underarm lymph nodes to other parts of the body. Although we're in the midst of October's Breast Cancer Awareness Month (BCAM), you may not be aware that:

• 98 percent of people with MBC will die of it, and 78 percent will perish within five years of diagnosis.

• Average survival with MBC is three years.

• The number of women dying annually hasn’t varied since the mid-1980s when BCAM was initiated. In 1988, approximately 40,000 women perished and in 2011, 40,931 women died of MBC.

• Each year, roughly 220,097 women and 2,078 men are diagnosed with breast cancer, with no improvement in 10 years."

Susan Zager's insight:

This article really shows the true facts about metastatic breast cancer. 

more...
Tambre Leighn's curator insight, October 21, 2014 11:01 AM

Realities far beyond the pink...

Scooped by Susan Zager
Scoop.it!

The Balancing Act Takes A Stand For Metatastic Breast Cancer @BalancingActTV

The Balancing Act Takes A Stand For Metatastic Breast Cancer @BalancingActTV | Breast Cancer News | Scoop.it
Today's show focuses on bringing awareness about metatastic breast cancer and an all-volunteer group committed to filling gaps in MBC research; plus hear from three women who have stage 4 breast cancer. The Balancing Act latest segments and shows. Watch us weekdays at 7AM airing on Lifetime Television Network. Topics of our show include the health and wellness of our views and to introduce new and exciting products in a fun social format.
Susan Zager's insight:

Today is Metastatic Breast Cancer Awareness Day. This is a great interview with CJ Corneliussen-James and Kelly Lange.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Pain like 'skin being peeled'

Pain like 'skin being peeled' | Breast Cancer News | Scoop.it

"My breast cancer went undiagnosed for eight weeks.

There is no blame to my GP at the time as I ended up with metaplastic breast cancer - and as with 0.02 per cent of women who have this deadly cancer, it presented like a cyst.

I owe my life to my breast surgeon who removed this fast-growing nightmare with deep, clear margins, however I ended up with severe nerve damage down the left side of my chest. This wonderful man even apologised but pffttt he saved my life, this pain is a small thing in comparison.

However, at times, it feels like my skin is being peeled off layer by layer. I am unable to bear even pure silk camisoles against my skin so I lie there bare-chested (in private of course!).

Chemotherapy didn't suit my body very well either, and I ended up for months enduring a mouth and throat full of abscesses. The pain was indescribable. "  

Susan Zager's insight:

This article is about a Metaplastic breast cancer patient who discusses all of the incredible side effects and other things that happen as a result of the awful disease. 

more...
Maria Fowler's curator insight, October 10, 2014 7:34 PM

A metaplastic breast cancer story

Scooped by Susan Zager
Scoop.it!

Explore Global breast cancer (HER2-, HER2+) industry analysis and epidemiology forecast to 2023 - WhaTech

Explore Global breast cancer (HER2-, HER2+) industry analysis and epidemiology forecast to 2023 - WhaTech | Breast Cancer News | Scoop.it
Epidemiologists forecast that the number of diagnosed incident cases of breast cancer in women in the 8MM is expected to grow to 1.21 million cases in 2023 at a rate of 4.23% per year during the forecast period. The number of five-year diagnosed prevalent cases in the 8MM is expected to increase by 43.0% over the next decade to 5.12 million cases in 2023.
Susan Zager's insight:

For the complete report go to: http://www.rnrmarketresearch.com/epicast-report-breast-cancer-her2-her2-epidemiology-forecast-to-2023-market-report.html#src=whatech


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

FDA Finalizes Guidance Aimed at Accelerating Approval for Some Breast Cancer Treatments | RAPS

FDA Finalizes Guidance Aimed at Accelerating Approval for Some Breast Cancer Treatments | RAPS | Breast Cancer News | Scoop.it
A new final guidance document issued by the US Food and Drug Administration (FDA) outlines the processes by which the regulator will accept surrogate endpoints to support the accelerated approval of treatments intended for high-risk early-stage breast cancer.
more...
No comment yet.